Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis

Gustavsen, Stefan; Hb, Søndergaard; Línnet, Kristían; Thomsen, Ragnar; Bs, Rasmussen; Ps, Sørensen; Sellebjerg, Finn; Ab, Oturai

doi:10.1016/j.msard.2020.102708

Cited by 9 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…( The Health Products Regulatory Authority, 2017 ; Abuhasira, et al, 2018 ; Krcevski-Skvarc, et al, 2018 ; Danish Medicines Agency, 2020 ; Gustavsen, et al, 2021 )…”

Section: Resultsmentioning

confidence: 99%

Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation

et al. 2022

View full text Add to dashboard Cite

Cannabis has long been regarded as a recreational substance in the Western world. The recent marketing authorization of some medicinal products of industrial origin and the introduction onto the market of inflorescences for medical use mean that medical doctors can now prescribe Cannabis-based medicines in those countries which allow it. Nevertheless, there is still considerable controversy on this topic in the scientific community. In particular, this controversy concerns: the plant species to be used; the pathologies that can be treated and consequently the efficacy and safety of use; the routes of administration; the methods of preparation; the type and dosage of cannabinoids to be used; and, the active molecules of interest. As such, although medical Cannabis has been historically used, the results of currently completed and internationally published studies are inconclusive and often discordant. In light of these considerations, the aim of this work is to analyse the current legislation in countries that allow the use of medical Cannabis, in relation to the impact that this legislation has had on clinical trials. First of all, a literature search has been performed (PubMed and SciFinder) on clinical trials which involved the administration of Cannabis for medical use over the last 3 years. Of the numerous studies extrapolated from the literature, only about 43 reported data on clinical trials on medical Cannabis, with these mainly being performed in Australia, Brazil, Canada, Denmark, Germany, Israel, Netherlands, Switzerland, the United Kingdom and the United States of America. Once the reference countries were identified, an evaluation of the legislation in relation to Cannabis for medical use in each was carried out via the consultation of the pertinent scientific literature, but also of official government documentation and that of local regulatory authorities. This analysis provided us with an overview of the different legislation in these countries and, consequently, allowed us to analyse, with greater awareness, the results of the clinical trials published in the last 3 years in order to obtain general interest indications in the prosecution of scientific research in this area.

show abstract

“…( The Health Products Regulatory Authority, 2017 ; Abuhasira, et al, 2018 ; Krcevski-Skvarc, et al, 2018 ; Danish Medicines Agency, 2020 ; Gustavsen, et al, 2021 )…”

Section: Resultsmentioning

confidence: 99%

Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A solid-phase extraction procedure was performed on prepared plasma samples. A detailed description of the methodology has previously been provided [22].…”

Section: Analysis Of Exo-and Endocannabinoidsmentioning

confidence: 99%

The peripheral endocannabinoid system and its association with biomarkers of inflammation in untreated patients with multiple sclerosis

Gustavsen

Olsson

Oturai

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeThe endocannabinoid system (ECS) has been found altered in patients with multiple sclerosis (MS). However, whether the ECS alteration is present in the early stage of MS remains unknown. First, we aimed to compare the ECS profile between newly diagnosed MS patients and healthy controls (HCs). Next, we explored the association of the ECS, biomarkers of inflammation, and clinical parameters in newly diagnosed MS patients.MethodsWhole blood gene expression of ECS components and levels of endocannabinoids in plasma were measured by real‐time quantitative polymerase chain reaction and ultra‐high‐pressure liquid chromatography–mass spectrometry, respectively, in 66 untreated MS patients and 46 HCs.ResultsNo differences were found in the gene expression or plasma levels of the selected ECS components between newly diagnosed MS patients and HCs. Interferon‐γ, encoded by the gene IFNG, correlated positively (ρ = 0.60) with the expression of G protein‐coupled receptor 55 (GPR55), and interleukin1β (IL1B) correlated negatively (ρ = −0.50) with cannabinoid receptor 2 (CNR2) in HCs.ConclusionsWe found no alteration in the peripheral ECS between untreated patients with MS and HC. Furthermore, our results indicate that the ECS has a minor overall involvement in the early stage of MS on inflammatory markers and clinical parameters when compared with HCs.

show abstract

Cannabis and Multiple Sclerosis

Ross

2023

Plant-Based Therapeutics, Volume 1

View full text Add to dashboard Cite

Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis

Cited by 9 publications

References 21 publications

Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation

Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation

The peripheral endocannabinoid system and its association with biomarkers of inflammation in untreated patients with multiple sclerosis

Cannabis and Multiple Sclerosis

Contact Info

Product

Resources

About